Printer Friendly

HAUSER AWARDED NEW PROJECT FROM THE NATIONAL CANCER INSTITUTE FOR A COMPOUND WITH POSSIBLE ANTI-HIV ACTIVITY

 BOULDER, Colo., June 24 /PRNewswire/ -- Hauser Chemical Research Inc. (NASDAQ: HAUS) announces a new agreement with the National Cancer Institute (NCI) for the "Isolation and Purification of Michellamine B from Crude Extracts of Ancistrocladus sp. Novum." NCI is exploring the anti-HIV activity of the compound. The project is valued at $314,500 over a six month period and is awarded under a Master Agreement that Hauser has with NCI.
 NCI has contracted with Hauser to prepare enough of the compound to permit preclinical evaluation of the drug's efficacy and usefulness before recommending it for clinical trials. Hauser will prepare the pure compound, michellamine B, from crude extract provided by the NCI. In addition, Hauser will apply its proprietary technologies to improve the isolation and purification of michellamine B in anticipation of a larger scale production in the future.
 In assays conducted by NCI, michellamine B has shown "in vitro" activity against a variety of human immunodeficiency viruses. The compound was first identified in 1991 by NCI. The plant from which the compound is extracted has been named Ancistrocladus korupensis after the national park in Cameroon where it was first identified. The plant is a vine which grows in the tree tops of the Cameroon forests in west central Africa. NCI is exploring cultivation of the plant in collaboration with scientists at the University of Yaunde in Cameroon for future supply.
 Dr. Randy Daughenbaugh, Hauser's chief technical officer, stated, "Hauser's team of scientists and our proprietary technology are extremely valuable in projects of this type. We look forward to helping NCI move ahead with its study of the usefulness of this new compound in the treatment of AIDS."
 In a similar program five years ago, Hauser began its work with taxol. "Continued involvement in early development of experimental compounds with NCI will lead to future product opportunities like taxol," according to Hauser's chief executive officer, Dr. Dean Stull. NCI efforts over the past two decades led to the development of TAXOL(R), which received Food and Drug Administration (FDA) approval for treatment of refractory ovarian cancer in December of 1992. Hauser is the only GMP (Good Manufacturing Practices) commercial producer of bulk taxol for human use.
 Hauser Chemical Research is the leader in specialty products from natural sources using its proprietary technologies. These products include natural flavor extracts for the food and beverage industry as well as natural compounds for pharmaceutical, cosmetic and veterinary applications. The company also provides interdisciplinary laboratory testing services, chemical engineering services and contract research and development through its Hauser Laboratories Division. The company is based in Boulder.
 -0- 6/24/93
 /CONTACT: Dean P. Stull or the Investor Relations Department of


Hauser Chemical Research, 303-443-4662/
 (HAUS)


CO: Hauser Chemical Research Inc.; National Cancer Institute ST: Colorado IN: MTC SU:

BB -- DV001 -- 5269 06/24/93 11:17 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 24, 1993
Words:472
Previous Article:FORD AND UAW OPEN CONTRACT TALKS
Next Article:FOUR CORDIS ANGIOPLASTY CATHETERS APPROVED FOR US MARKET RELEASE
Topics:


Related Articles
HAUSER AWARDED MASTER AGREEMENTS FROM THE NATIONAL CANCER INSTITUTE
HAUSER ANNOUNCES OUTSTANDING FISCAL YEAR END RESULTS
HAUSER ANNOUNCES THAT ITS SUPPLY AGREEMENT WITH BRISTOL-MYERS/SQUIBB FOR PACLITAXEL (TAXOL) WILL NOT BE EXTENDED
HAUSER ANNOUNCES AGREEMENT WITH COLGATE ORAL PHARMACEUTICALS TO PRODUCE SANGUINARIA EXTRACT
KILLER T CELLS REPORTED AS A POTENTIAL GENE THERAPY FOR VIRAL DISEASES AND CANCER
XENOVA AWARDED GRANT IN SUPPORT OF CANCER DRUG CLINICAL DEVELOPMENT PROGRAM
Illinois Biotech Firm, State of Sarawak, Malaysia, Form Company to Advance New AIDS Drug
Demeter BioTechnologies, Ltd. Awarded SBIR Grant For Research to Prevent Disease Transmission
GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003; $500,000 in Research Grants Awarded to Five Researchers Working Toward...
Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters